Nuclear medicine in the management of thyroid disease

Expert Review of Anticancer Therapy

Volumn 8, Issue 9, 2008, Pages 1425-1431

  Buscombe, John ^a   Hirji, Hassan ^a   Witney Smith, Caroline ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

131I; Lithium retinoids gene therapy; PET; Thyroid cancer; Thyroid disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; BLEOMYCIN; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DEPREOTIDE TC 99M; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 131; LITHIUM; LUTETIUM 177; PACLITAXEL; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; RECOMBINANT THYROTROPIN; RETINOIC ACID; SODIUM IODIDE SYMPORTER; SOMATOSTATIN; YTTRIUM 90;

ANAPLASTIC CARCINOMA; CANCER CLASSIFICATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DOWN REGULATION; GOITER; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; ISOTOPE LABELING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; REVIEW; THYROID ADENOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 55249116808     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.9.1425     Document Type: Review

References (33)

1. Scheiden R, Keipes M, Bock C, Dippel W, Kieffer N, Capesius C. Thyroid cancer in Luxembourg: a national population-based data report (1983-1999). BMC Cancer 6, 102 (2006).
2. Piesko I, Macfarlane GJ, Obsitnikova A, Vlasak V, Kramarova E. Thyroid cancer in Slovakia, 1968-1990: incidence, mortality and histological types. Eur. J. Cancer Prev. 3, 345-349 (1994).
3. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin. Endocrinol. (Oxf.) 62, 156-162 (2005).
4. Patel NN, Abraham P, Buscombe J, Vanderpump MP The cost effectiveness of treatment modalities for thyrotaxicosis in a U.K. center. Thyroid 16, 593-598 (2006).
5. Akin F, Yaylali GF, Bastemir M. The use of lithium carbonate in the preparation for definitive therapy in hyperthyroid patients. Med. Princ. Pract. 17, 167-170 (2008).
6. Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR Radioiodine therapy and Graves' ophthalmopathy. J. Nucl. Med. 49, 923-930 (2008).
7. Yanir Y, Doweck I. Regional metastases in well-differentiated thyroid carcinoma: pattern of spread. Laryngoscope 118, 433-436 (2008).
8. Moradi T, Nordqvist T, Allebeck P, Galanti MR. Risk of thyroid cancer among Iranian immigrants in Sweden. Cancer Causes Control 3, 221-226 (2008).
9. Kushchayeva Y, Duh QY, Kebebew E, D'Avanzo A, Clark OH. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am. J. Surg. 195, 457-462 (2008).
10. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr. Pract. 6, 469-476 (2000).
11. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77, 2574-2580 (1996).
12. Bal CS, Kumar A Pant GS. Radioiodine dose for remnant alblation in differentiated thyroid carcinoma: a randomised clinical trial in 509 patients. J. Clin. Endocriol. Metab. 89, 1666-16673 (2004).
13. Dietlein M, Dressler J, Eschner W et al. Deutsche Gesellschaft für Nuklearmedizin; Deutsche Gesellschaft für Medizinische Physik. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin. 46, 213-219 (2007).
14. Lippi F, Capezzone M, Angelini F et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur. J. Endocrinol. 144, 5-11 (2001).
15. Borget I, Remy H, Chevalier J et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur. J. Nucl. Med. Mol. Imaging 35(8), 1457-1463 (2008).
16. Mallick U, Harmer C, Hackshaw A. The HiLo Trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 20, 325-326 (2008).
17. Pons F, Carrió I, Estorch M, Ginjaume M, Pons J, Milian R. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin. Nucl. Med. 12, 644-647 (1987).
18. Koong SS, Reynolds JC, Movius EG et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 84, 912-916 (1999).
19. Liu YY, Stokkel MP, Pereira AM et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur. J. Endocrinol. 154, 525-531 (2006).
20. Liu YY, Stokkei MP, Morreau HA, Pereira AM, Romijn JA, Smit JW. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf.) 68, 605-609 (2008).
21. Shen DH, Marsee DK, Schaap J et al. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther. 11, 161-169 (2004).
22. Lim SJ, Paeng JC, Kim SJ, Kim SY, Lee H, Moon DH. Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment. J. Nucl. Med. 48, 398-404 (2007).
23. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current status and future, prospects Thyroid 14, 424-434 (2004).
24. Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur. J. Endocrinol. 143, 15-24 (2000).
25. 18F-FDG PET/ CT in patients with suspected recurrent or metastatic well differentiated thyroid cancer. J. Nucl. Med. 48, 221-226 (2007).
26. 131I ablation. Q. J. Nucl. Med. Mol. Imaging 52, 2-8 (2008).
27. 18F-FDG PET. Eur. J. Nucl. Med. Mol. Imaging 32, 1144-1151 (2005).
28. 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J. Clin. Endocrinol. Metab. 91, 3997-4000 (2006).
29. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med. 32, 148-555 (2002).
30. Busnardo B, Daniele O, Pelizzo MR et al. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. Endocrinol. Invest. 23, 755-761 (2000).
31. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 92, 2902-2909 (2007).
32. Kaltsas G, Korbonits M, Heintz E et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86, 895-902 (2001).
33. Oyen WJ, Bodei L, Giammarile F et al. Targeted therapy in nuclear medicine - current status and future prospects. Ann. Oncol. 18, 1782-1792 (2007).